| Drug Class | ARV Name | Development Phase | Company |
|---|---|---|---|
| Non-Nucleoside Reverse Transcriptase Inhibitor | Rilpivirine | Phase III injectable (oral agent approved) | Janssen |
| Integrase Inhibitor | Cabotegravir | Phase III injectable | ViiV |
| Nucleoside/Nucleotide Reverse Transciptase Inhibitor (NRTI) | EFdA | Phase I | Merck |
| Tenofovir alafenamide fumarate (TAF) | Preclinical implant (oral agent approved) | Gilead | |
| GS-9131 | Preclinical/Phase I | Gilead | |
| Capsid Inhibitor | GS-CA1 | Preclinical | Gilead |